InformTx Therapeutic Drug Monitoring for IBD Patients Launched by Miraca Life Sciences

InformTx Therapeutic Drug Monitoring for IBD Patients Launched by Miraca Life Sciences
Miraca Life Sciences, an independent anatomic pathology lab based in Irving, Texas, is expanding into clinical pathology testing for patients with inflammatory bowel disease (IBD). Miraca's new InformTx therapeutic drug monitoring (TDM) service is based on technology and raw materials licensed from the French firm Theradiag, which has been offering TDM assays in Europe for years under the name LISA TRACKER. InformTx testing assesses drug and anti-drug antibody blood levels for the biologic drugs infliximab (Remicade), adalimumab (Humira), certolizumab (Cimzia), and vedolizumab (Entyvio), mainly addressing IBDs such as Crohn's disease and ulcerative colitis. InformTx makes monitoring for certolizumab and vedolizumab available in the U.S. market for the first time, with no other U.S. medical lab offering this full set of four drug monitoring tests. Theradiag estimates that more than 330,000 IBD patients in the U.S. are treated with biologic drugs -- twice as many as in Europe. Theradiag will receive royalties on Miraca Life Sciences' sales in the U.S. "Miraca Life Sciences' launch of our first four tests in the USA is a major milestone in our geographical expansion strategy and represents a source of large potential sales in the years to come," said Theradiag CEO Michel Finance in a press release. "Its expertise and knowledge of the U.S. market make it the ideal partner to develop our LISA TRACKER range in the United States. The partnership enables us to make our biotherapy monitoring tests available to U.S. clinicians, helping them to optimize biotherapy treatments." Miraca Life Sciences' laboratory in Phoenix, Arizona has been certified by CLIA and accredited by the College of American Pathologists. InformTx testing has been ramping up since May 2,
Subscribe or to access all post and page content.